These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 9256134)

  • 41. Phase I trial of low-dose continuous topotecan infusion in patients with cancer: an active and well-tolerated regimen.
    Hochster H; Liebes L; Speyer J; Sorich J; Taubes B; Oratz R; Wernz J; Chachoua A; Raphael B; Vinci RZ
    J Clin Oncol; 1994 Mar; 12(3):553-9. PubMed ID: 8120553
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Increased 9-aminocamptothecin dose requirements in patients on anticonvulsants. NABTT CNS Consortium. The New Approaches to Brain Tumor Therapy.
    Grossman SA; Hochberg F; Fisher J; Chen TL; Kim L; Gregory R; Grochow LB; Piantadosi S
    Cancer Chemother Pharmacol; 1998; 42(2):118-26. PubMed ID: 9654111
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Phase I study of a weekly schedule of irinotecan, high-dose leucovorin, and infusional fluorouracil as first-line chemotherapy in patients with advanced colorectal cancer.
    Vanhoefer U; Harstrick A; Köhne CH; Achterrath W; Rustum YM; Seeber S; Wilke H
    J Clin Oncol; 1999 Mar; 17(3):907-13. PubMed ID: 10071283
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Irinotecan in combination with fluorouracil in a 48-hour continuous infusion as first-line chemotherapy for elderly patients with metastatic colorectal cancer: a Spanish Cooperative Group for the Treatment of Digestive Tumors study.
    Sastre J; Marcuello E; Masutti B; Navarro M; Gil S; Antón A; Abad A; Aranda E; Maurel J; Valladares M; Maestu I; Carrato A; Vicent JM; Díaz-Rubio E;
    J Clin Oncol; 2005 May; 23(15):3545-51. PubMed ID: 15908665
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Multicenter phase II study of CPT-11 fractionated over two days with bimonthly leucovorin and 5-fluorouracil in patients with metastatic colorectal cancer.
    Recchia F; Nuzzo A; Lalli A; Di Lullo L; De Filippis S; Saggio G; Di Blasio A; Rea S
    Anticancer Res; 2003; 23(3C):2903-8. PubMed ID: 12926132
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Phase I and pharmacologic study of 9-aminocamptothecin colloidal dispersion formulation in patients with refractory or relapsed acute leukemia.
    Vey N; Kantarjian H; Tran H; Beran M; O'Brien S; Bivins C; Giles F; Cortes J; Cheson B; Arbuck S; Estey E
    Ann Oncol; 1999 May; 10(5):577-83. PubMed ID: 10416008
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Phase II trial of intravenous CI-980 (NSC 370147) in patients with metastatic colorectal carcinoma. Model for prospective evaluation of neurotoxicity.
    Pazdur R; Meyers C; Diaz-Canton E; Abbruzzese JL; Patt Y; Grove W; Ajani J
    Am J Clin Oncol; 1997 Dec; 20(6):573-6. PubMed ID: 9391543
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. CPT-11 Gastrointestinal Cancer Study Group.
    Shimada Y; Yoshino M; Wakui A; Nakao I; Futatsuki K; Sakata Y; Kambe M; Taguchi T; Ogawa N
    J Clin Oncol; 1993 May; 11(5):909-13. PubMed ID: 8487053
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients. Digestive Group of French Federation of Cancer Centers.
    Bécouarn Y; Ychou M; Ducreux M; Borel C; Bertheault-Cvitkovic F; Seitz JF; Nasca S; Nguyen TD; Paillot B; Raoul JL; Duffour J; Fandi A; Dupont-André G; Rougier P
    J Clin Oncol; 1998 Aug; 16(8):2739-44. PubMed ID: 9704726
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A Phase II Trial of Combined Chemotherapy with Oral S-1 and 24-Hour Infusions of Irinotecan plus Bevacizumab in Patients with Metastatic Colorectal Cancer.
    Sadahiro S; Suzuki T; Tanaka A; Okada K; Saito G; Kamijo A
    Oncology; 2015; 88(6):353-9. PubMed ID: 25592116
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Sequence effect of irinotecan and fluorouracil treatment on pharmacokinetics and toxicity in chemotherapy-naive metastatic colorectal cancer patients.
    Falcone A; Di Paolo A; Masi G; Allegrini G; Danesi R; Lencioni M; Pfanner E; Comis S; Del Tacca M; Conte P
    J Clin Oncol; 2001 Aug; 19(15):3456-62. PubMed ID: 11481350
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Phase II study of weekly irinotecan (CPT-11) as second-line treatment of patients with advanced colorectal cancer.
    Cassinello J; López-Alvarez P; Martínez-Guisado A; Valladares M; Huidobro G; López R; Bohn U; Sevilla I; Ballesteros P; Jorge M; Pérez-Carrión R; Fernández JL; Dorta J
    Med Oncol; 2003; 20(1):37-43. PubMed ID: 12665683
    [TBL] [Abstract][Full Text] [Related]  

  • 53. First-line treatment with irinotecan and raltitrexed in metastatic colorectal cancer. Mature results of a multicenter phase II study.
    Aparicio J; Vicent JM; Maestu I; Bosch C; Galán A; Busquier I; Llorca C; Garcerá S; Campos JM; López-Tendero P; Balcells M
    Oncology; 2005; 68(1):58-63. PubMed ID: 15809521
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Phase II trial of uracil and tegafur plus oral leucovorin: an effective oral regimen in the treatment of metastatic colorectal carcinoma.
    Pazdur R; Lassere Y; Rhodes V; Ajani JA; Sugarman SM; Patt YZ; Jones DV; Markowitz AB; Abbruzzese JL; Bready B
    J Clin Oncol; 1994 Nov; 12(11):2296-300. PubMed ID: 7964943
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A randomized phase II trial of pemetrexed plus irinotecan (ALIRI) versus leucovorin-modulated 5-FU plus irinotecan (FOLFIRI) in first-line treatment of locally advanced or metastatic colorectal cancer.
    Underhill C; Goldstein D; Gorbounova VA; Biakhov MY; Bazin IS; Granov DA; Hossain AM; Blatter J; Kaiser C; Ma D
    Oncology; 2007; 73(1-2):9-20. PubMed ID: 18334829
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Irinotecan and chronomodulated infusion of 5-fluorouracil and folinic acid in the treatment of patients with advanced colorectal carcinoma: a phase I study.
    Garufi C; Dogliotti L; D'Attino RM; Tampellini M; Aschelter AM; Pugliese P; Perrone M; Nisticó C; Comis S; Terzoli E
    Cancer; 2001 Feb; 91(4):712-20. PubMed ID: 11241238
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Triplet combination with irinotecan plus oxaliplatin plus continuous-infusion fluorouracil and leucovorin as first-line treatment in metastatic colorectal cancer: a multicenter phase II trial.
    Souglakos J; Mavroudis D; Kakolyris S; Kourousis Ch; Vardakis N; Androulakis N; Agelaki S; Kalbakis K; Tsetis D; Athanasiadis N; Samonis G; Georgoulias V
    J Clin Oncol; 2002 Jun; 20(11):2651-7. PubMed ID: 12039926
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Efficacy and safety of cetuximab/irinotecan in chemotherapy-refractory metastatic colorectal adenocarcinomas: a clinical practice setting, multicenter experience.
    Gebbia V; Del Prete S; Borsellino N; Ferraù F; Tralongo P; Verderame F; Leonardi V; Capasso E; Maiello E; Bordonaro R; Stinco S; Agostara B; Barone C
    Clin Colorectal Cancer; 2006 Mar; 5(6):422-8. PubMed ID: 16635281
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A phase II trial of interferon alpha-2b with folinic acid and 5-fluorouracil administered by 4-hour infusion in metastatic colorectal carcinoma.
    Kreuser ED; Hilgenfeld RU; Matthias M; Hoksch B; Boewer C; Oldenkott B; Lenk H; Wiener N; Boese-Landgraf J; Schalhorn A
    Semin Oncol; 1992 Apr; 19(2 Suppl 4):57-62. PubMed ID: 1553576
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Weekly irinotecan plus protracted venous fluorouracil infusion (WI-FI) in advanced colorectal cancer: a phase II study.
    Oliva C; Pochettino P; Bergnolo P; Boglione A; Cutin SC; Inguì M; Dal Canton O; Garetto F; Biscardi M; Berno E; Comandone A;
    Anticancer Res; 2008; 28(4C):2327-32. PubMed ID: 18751414
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.